{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:23Z","timestamp":1790575043329,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Modified FOLFIRINOX (mFFX) and gemcitabine plus nab-paclitaxel (GnP) are both recommended as standard first-line regimens for unresectable pancreatic cancer (PC). However, direct head-to-head comparative evidence remains scarce, and prior studies have largely failed to distinguish mFFX from standard FOLFIRINOX (sFFX). We systematically compared mFFX with GnP to evaluate their efficacy and toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched for randomized controlled trials (RCTs) and observational studies comparing mFFX with GnP as first-line therapy for unresectable PC published between January 2013 and May 2026. Overall survival (OS) and progression-free survival (PFS) were assessed using hazard ratios (HRs). Objective response rate (ORR) and disease control rate (DCR) were evaluated using risk ratios (RRs). Events of toxicities were assessed using odds ratios (ORs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five studies (three RCTs and two retrospective studies) involving 1204 patients (578 in the mFFX arm and 626 in the GnP arm) were included. Compared with GnP, mFFX was associated with a shorter OS (HR 1.26, 95% CI 1.09\u20131.45;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.002) and PFS (HR 1.21, 95% CI 1.04\u20131.40;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.01), along with a borderline lower DCR (RR 0.90, 95% CI 0.81\u20131.00;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.05; I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a062%), which was consistent across RCTs (RR 0.88, 95% CI 0.81\u20130.94; I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%) but not observed in retrospective studies (RR 0.96, 95% CI 0.71\u20131.29; I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a087%), and ORR did not differ significantly between the two regimens. As for toxicity profiles, mFFX showed an elevated incidence of grade \u22653 diarrhea (OR 5.63) and anorexia (OR 4.44). By contrast, grade \u22653 neutropenia (OR 0.66) and white blood cell decrease (OR 0.49) occurred more frequently under GnP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GnP was associated with more favorable OS and PFS than mFFX, a borderline DCR advantage, and distinct toxicity profiles. Given the modest effect size and the limitations of this study, clinical decision-making should integrate patient age, performance status, and anticipated second-line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251175959.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1913824","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:35Z","timestamp":1790574335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Chunle","family":"Hu","sequence":"first","affiliation":[{"name":"The First Clinical Institute, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhan","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Li","sequence":"additional","affiliation":[{"name":"The First Clinical Institute, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Ren","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Provincial Key Laboratory of Digestive System Diseases in Guizhou Province, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B5","article-title":"NCCN guidelines updates: Pancreatic cancer","volume":"17","author":"Tempero","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v10.i11.421","article-title":"Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer","volume":"10","author":"Kang","year":"2018","journal-title":"World J Gastrointest Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31829e2006","article-title":"Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma","volume":"42","author":"Mahaseth","year":"2013","journal-title":"Pancreas"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.45","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer","volume":"114","author":"Stein","year":"2016","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1604","article-title":"Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the first-line treatment for pancreatic cancer: A systematic review and meta-analysis","volume":"14","author":"Merza","year":"2023","journal-title":"World J Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: A systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00936","article-title":"Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or S-1, irinotecan, and oxaliplatin versus nab-paclitaxel + gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): A randomized, open-label, phase II\/III trial","volume":"43","author":"Ohba","year":"2025","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00436","article-title":"PASS-01: Randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer","volume":"43","author":"Knox","year":"2025","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12885-021-08277-7","article-title":"Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: A propensity score matching approach","volume":"21","author":"Chun","year":"2021","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/ijmr.ijmr_980_21","article-title":"Modified FOLFIRINOX compared to gemcitabine & nab-paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis","volume":"157","author":"Ramaswamy","year":"2023","journal-title":"Indian J Med Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/mpa.0000000000001801","article-title":"Comparison of treatment outcomes between gemcitabine with nab-paclitaxel and modified FOLFIRINOX for first-line chemotherapy in metastatic and recurrent pancreatic cancer: Propensity score matching","volume":"50","author":"Mie","year":"2021","journal-title":"Pancreas"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.48095\/ccko2024331","article-title":"Gemcitabine\/nab-paclitaxel in first line treatment of advanced pancreatic cancer - head-to-head comparison with the mFOLFIRINOX regimen","volume":"37","author":"Tom\u00e1\u0161ek","year":"2024","journal-title":"Klin Onkol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2021.03.040","article-title":"Gemcitabine\/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis","volume":"151","author":"Riedl","year":"2021","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12885-024-13386-0","article-title":"Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: A multicentre retrospective study","volume":"25","author":"Aseafan","year":"2025","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231175441","article-title":"Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: A systematic review, evidence-mapping, and meta-analysis","volume":"15","author":"Jung","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.042","article-title":"Impact of first-line FOLFIRINOX versus gemcitabine\/nab-paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry","volume":"174","author":"Santucci","year":"2022","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34271","article-title":"FOLFIRINOX or gemcitabine\/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world","volume":"152","author":"Marschner","year":"2023","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16199","article-title":"Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma","volume":"5","author":"Klein-Brill","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16329","article-title":"Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications","volume":"115","author":"Doi","year":"2024","journal-title":"Cancer Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100881","article-title":"A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing","volume":"8","author":"Paiella","year":"2023","journal-title":"ESMO Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03293-x","article-title":"Toward an individualized strategy in perioperative chemotherapy for pancreatic cancer","volume":"133","author":"Lee","year":"2025","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13883","article-title":"Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX","volume":"110","author":"Shirasu","year":"2019","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00280-020-04206-w","article-title":"FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: A multicenter, retrospective study","volume":"87","author":"Umemoto","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.185","article-title":"Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer","volume":"115","author":"Chiorean","year":"2016","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00795","article-title":"Gemcitabine and paclitaxel versus gemcitabine alone after 5-fluorouracil, oxaliplatin, and irinotecan in metastatic pancreatic adenocarcinoma: A randomized phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER study","volume":"42","author":"De La Fouchardi\u00e8re","year":"2024","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1186\/s12885-021-08605-x","article-title":"Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"20152","DOI":"10.1038\/s41598-021-99647-5","article-title":"Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: A systematic review and meta-analysis","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030359","article-title":"Managing irinotecan-induced diarrhea: A comprehensive review of therapeutic interventions in cancer treatment","volume":"18","author":"Yang","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040484","article-title":"Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: A systematic review and meta-analysis","volume":"11","author":"Pusceddu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad178","article-title":"A novel HRD signature is predictive of FOLFIRINOX benefit in metastatic pancreatic cancer","volume":"28","author":"Chen","year":"2023","journal-title":"Oncologist"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1164","article-title":"Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3149","article-title":"Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma","volume":"31","author":"Ardalan","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1913824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:36Z","timestamp":1790574336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1913824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1913824"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1913824","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1913824"}}